A better delivery system brings anti-inflammatory therapies to critical sites
Arthritis flares — the unpredictable and often sudden worsening of arthritis symptoms — can be debilitating. These episodes can make the management of inflammatory arthritis, which includes rheumatoid arthritis and psoriatic arthritis, challenging for patients and physicians.
But investigators at Harvard-affiliated Brigham and Women’s Hospital (BWH) have found that flares may also represent an important opportunity for improving treatment options.
In experiments carried out in the lab, BWH bioengineers have developed a hydrogel — a soft, flexible material that can be loaded with arthritis drugs and injected locally into an inflamed joint. Instead of delivering the drug continuously at a steady rate, the hydrogel is designed to respond to increased disease activity during flares, releasing the drug when symptoms worsen. The team’s laboratory-based findings are published this week in Nature Communications and investigators are working on next steps to bring their technology closer to the clinic.
“Arthritis represents a huge unmet clinical need,” said co-senior author Jeff Karp,a bioengineer and principal investigator at BWH and Harvard Medical School (HMS) professor of medicine. “Although new therapeutics have been developed, many have had systemic, toxic effects. We wanted to design a delivery system that could be efficient, deliver drugs locally, and release drugs in response to inflammation.”
The newly created flare-responsive hydrogel is made from triglycerol monostearate (TG-18), a compound from the Food and Drug Administration’s list of “generally recognized as safe” compounds. TG-18 is a molecule capable of self-assembling, meaning that it can form a gel-like structure comprising fibers. This structure can be easily injected as a suspension. In this study, the TG-18 hydrogel was loaded with triamcinolone acetonide (TA), used here as a model drug, but could potentially be loaded with many other kinds of anti-inflammatory compounds.
“The hydrogel is designed so that drug release is triggered by the activity of specific, arthritis-related enzymes that are increased during flares. To test the TG-18 hydrogel, we exposed the gel to several different kinds of environments mimicking conditions in arthritic joints,” said Nitin Joshi, co-first author on the work and an instructor of medicine at BWH and HMS.
When the gel was incubated in synovial fluid from a healthy human joint, drug release was minimal, but when incubated in synovial fluid from a patient with rheumatoid arthritis, the drug was readily released from the hydrogel. Importantly, the drug supply was not exhausted in one spike of synovial fluid — instead, it could be released in response to multiple spikes over time. The team also tested the hydrogel’s effects on cells from cartilage and joints, and found that it appeared to be safe.
The team further tested the clinical efficacy of the TG-18 hydrogel in a mouse model of inflammatory arthritis. They chose the K/BxN serum transfer model, in which disease severity can be precisely controlled, which allowed them to test the hydrogel in animals with different degrees of arthritis severity. They found that when arthritis was more severe, the locally injected hydrogel degraded more rapidly, corresponding to increased drug release. Swelling and severity of arthritis diminished in response to the drug-loaded hydrogel.
One of the advantages of the hydrogel is that it offers the promise of treating arthritis specifically in the joints where the disease is flaring, rather than delivering a drug throughout the body.
“Local therapy could be a viable treatment option for patients with only one or a few inflamed joints, said co-corresponding author Joerg Ermann, a rheumatologist in the BWH Division of Rheumatology, Immunology, and Allergy and HMS instructor in medicine. “Moreover, if a patient is already on a systemic drug but is experiencing a flare in a limited number of joints, we could specifically treat these joints rather than switching to systemic therapy or adding another systemic drug. Having this option would substantially increase our ability to successfully manage arthritis flares in the clinic.”
The team will continue testing the hydrogel in preclinical models to further validate it, and continue to advance toward human clinical trials. The technology has been licensed by Alivio Therapeutics, which is developing therapies to treat inflammatory disorders via targeted disease immunomodulation.
Learn more: Treating inflammatory arthritis with hydrogel
The Latest on: Inflammatory arthritis
via Google News
The Latest on: Inflammatory arthritis
- How occupational therapy can help people with arthritis on April 17, 2019 at 6:13 am
Conservative estimates from the AF suggest 54 million adults in the United States currently have arthritis, though the organization reports that a recent study suggested as many as 91 million might be ... […]
- Recent Research Now Suggests Ashwagandha Helps in Cases of Rheumatoid Arthritis on April 17, 2019 at 2:31 am
This is why it is always best to reduce inflammation through diet. When it comes to naturally remedying rheumatoid arthritis, it is essential to consider what certain natural remedies can offer. […]
- Non-invasive vagus nerve stimulation shows promise for treatment of rheumatoid arthritis on April 17, 2019 at 12:48 am
"This clinical research suggests that non-invasive stimulation could suppress inflammation in rheumatoid arthritis patients," said Kevin J. Tracey, MD, president and CEO of the Feinstein Institute ... […]
- Inflammatory arthritis may impact sexual function on April 16, 2019 at 7:42 am
medwireNews: Findings from a systematic review suggest that sexual dysfunction is common among both men and women with inflammatory arthritis (IA), highlighting the importance of including sexual ... […]
- New Study Suggests Cannabis May Be Used to Treat Rheumatoid Arthritis on April 16, 2019 at 4:21 am
Cannabis may be an effective treatment for rheumatoid arthritis, according to a new ... RA” and called for further study into the anti-inflammatory properties of CBD. Dr. Benjamin Caplan ... […]
- New Study Suggests Cannabis May Be Effective For Rheumatoid Arthritis, And Why It May Not Matter on April 15, 2019 at 1:51 pm
And Baby Boomers and older adults suffering from RA and other inflammatory conditions of the joints are ... has helped thousands of patients over the age of 65 treat their arthritis with cannabinoid ... […]
- Dr. Haqqani: New information on the impact of smoking on rheumatoid arthritis on April 15, 2019 at 4:44 am
Rheumatoid arthritis causes the immune system to mistakenly focus on joints, including elbows, wrists, hands, knees and ankles, instead of fighting bacteria and viruses. Swelling and pain around the ... […]
- Calprotectin levels separate septic arthritis from other inflammatory arthritides on April 15, 2019 at 2:09 am
medwireNews: Levels of calprotectin in the synovial fluid can be used to discriminate patients with septic arthritis from those with pseudogout and rheumatoid arthritis (RA), shows a report published ... […]
- What is Reactive Arthritis? on April 14, 2019 at 9:55 pm
Reactive arthritis (also called “Reiter syndrome”) is a painful inflammatory joint disease. The condition is relatively rare and is more common in men in their twenties and thirties. Inflammation ... […]
via Bing News